Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2019
Reporting Period: Fourth Quarter and Full Year ended December 31, 2018
Status: Emerging Growth Company
Key Financial Metrics
This filing serves as a notification of the release of financial results. The specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not contained within the text of this Form 8-K. The filing references a press release (Exhibit 99.1) titled "Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results" for detailed figures.
Material Changes
The filing does not provide specific data regarding material changes versus prior periods. It solely announces the reporting of results for the quarter and year ended December 31, 2018.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing the company's financial results and likely management commentary, but the text of the 8-K itself does not include specific guidance, outlook, or risk factors.
Legal Disclaimer: The information in this report and the accompanying exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filing by the company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 12, 2019) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate, as this is a pre-revenue biopharmaceutical company.
- Check for any updates on clinical trial progress for the company's lead candidates mentioned in the press release.
- Confirm the status of the company's emerging growth company election and its implications for financial reporting.